viewNetscientific PLC

NetScientific hails commercial launch of breakthrough cancer detection device

The official launch took place in San Francisco at the Molecular Medicine Tri Conference.

The fully-automated technology is able to collect circulating tumour cells
NetScientific PLC (LON:NSCI) said its investee company Vortex Biosciences has begun the commercial launch of its VTX1 Liquid Biopsy System.
The fully-automated technology offers a breakthrough in early cancer detection in that it is able to collect circulating tumour cells (CTC) from the bloodstream that provide the tell-tale sign of the killer disease.
"We believe the technology has several key advantages over current approaches to CTC isolation and has the potential to make a meaningful impact on cancer research and assist the development of innovative diagnostics and therapeutics," said NetScientific chief executive François Martelet. 
"The commercial launch is a critical milestone for Vortex and brings our portfolio company closer to significant value creation."
The AIM-listed investment company owns 95% of Votex having invested just over £13mln in the business.
The official launch took place in San Francisco at the Molecular Medicine Tri Conference.

Quick facts: Netscientific PLC

Price: 61.75 GBX

Market: AIM
Market Cap: £9.21 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Netscientific PLC named herein, including the promotion by the Company of Netscientific PLC in any Content on the Site, the Company receives...


Investor Update: ANGLE reports positive data from Parsortix FDA clinical study

Top stories from the Proactive Investors UK newsroom: ANGLE PLC (LON:AGL) has received positive results from its Parsortix FDA clinical study for metastatic breast cancer. The 400-subject clinical study will support an application for Class II regulatory clearance for Parsortix in the...

on 31/5/19

2 min read